Oxford Biomedica PLC Director Dealings (1314H)
01 December 2020 - 11:17PM
UK Regulatory
TIDMOXB
RNS Number : 1314H
Oxford Biomedica PLC
01 December 2020
Director Dealings
Oxford, UK - 01 December 2020: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB a leading gene and cell
therapy group, today announces that Dr. Andrew Heath, a
Non-Executive Director of the Group, sold 28,597 ordinary shares of
50p each ("Ordinary Shares") in the Company on 30 November 2020 on
the London Stock Exchange at a price of 869.2p.
15,756 Ordinary Shares were sold by Dr. Heath's wife (Eva
Lackner) on 30 November 2020 on the London Stock Exchange at a
price of 868.8p and are therefore considered a beneficial holding
of Dr. Heath.
Following these sales Dr. Andrew Heath holds 11,628 shares
representing 0.01% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Dr. Andrew Heath
2. Reason for the notification
a. Position/status Non-Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Disposal of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP8.69 28,597
e. Aggregated information 28,597
* Aggregated volume GBP8.6922
GBP248,570.84
* Price
* Aggregated total
f. Date of the transaction 2020-11-30
g. Place of the transaction London Stock Exchange, Main Market (XLON)
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Eva Lackner
2. Reason for the notification
a. Position/status Person closely associated with Dr. Andrew
Heath, Non- Executive Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford Biomedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford Biomedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Disposal of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP8.69 15,756
e. Aggregated information 15,756
* Aggregated volume GBP8.6883
GBP136,892.85
* Price
* Aggregated total
f. Date of the transaction 2020-11-30
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 82,294,468 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford Biomedica plc: Tel: +44 (0)1865 783 000
Natalie Walter, Company Secretary
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Bristol Myers Squibb,
Sanofi, Sio Gene Therapies, Orchard Therapeutics, Santen,
Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy
Consortium and Imperial Innovations, through which it has long-term
economic interests in other potential gene and cell therapy
products. Additionally the group has signed a Clinical and
Commercial Supply Agreement with AstraZeneca for manufacture of the
adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica
is based across several locations in Oxfordshire, UK and employs
more than 550 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHMZMGZZMFGGZM
(END) Dow Jones Newswires
December 01, 2020 07:17 ET (12:17 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024
